Epilepsy

Specifically, the alignment relates to a separate, planned clinical trial referred to as ASPIRE.

The director of the Center for Clinical Ethics at Yale New Haven Health provided insights on newly published guidelines for functional seizures, stressing the reasons for systemic psychiatric assessment and careful seizure characterization. [WATCH TIME: 3 minutes]

The chief medical officer at Xenon Pharmaceuticals provided clinical insights on promising long-term, phase 2 data testing azetukalner, a first-in-class Kv7 channel opener, in patients with focal onset seizures. [WATCH TIME: 4 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 23, 2026.

Pediatric specialists stressed that the future of epilepsy care may involve embedding behavioral health clinicians in specialty clinics to identify and treat depression early, improve quality of life, and potentially reduce seizure burden. [WATCH TIME: 3 MINUTES]

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Benjamin Tolchin, MD, MS, FAAN. [LISTEN TIME: 23 minutes]

Pediatrics specialists discussed approaches to assessing depressive symptoms that may overlook key risk factors, highlighting the need for improved self-report measures, developmentally appropriate tools, and more precise symptom characterization. [WATCH TIME: 3 MINUTES]

Here's some of what is coming soon to NeurologyLive® this week.

Pediatrics specialists discussed key methodological limitations of a recently published study, including variability across sites, reliance on caregiver-report measures, and the lack of developmentally appropriate tools for assessing depression in youth with intellectual disabilities. [WATCH TIME: 4 MINUTES]

Pediatric specialists reflected on the challenges and gaps in assessing depressive and anxiety symptoms among youth with epilepsy, emphasizing that patients with lower IQs are often excluded from research and clinical screening. [WATCH TIME: 3 MINUTES]

Neurology News Network for the week ending January 17, 2025. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 16, 2026.

Pediatric specialists reflected on the goal and findings of the study, describing the elevated prevalence of depressive symptoms among youth with epilepsy and highlighting temporal lobe epilepsy as a particularly high-risk subgroup. [WATCH TIME: 2 MINUTES]

The director of Cleveland Clinic's Gamme Knife Center and Head Section of Spine Tumors writes about how stereotactic radiosurgery has transformed modern neurology and neurosurgery

A trio of clinician authors provided insights on a recently published paper assessing youths with refractory epilepsy and ways to combat depressive symptoms.

The FDA approved Sentynl Therapeutics’ copper histidinate for the treatment of pediatric Menkes disease, a rare genetic neurodegenerative disorder, following an earlier complete response letter.

Those from the clinical community may expect to hear data from the registrational trial assessing zorevunersen in Dravet syndrome by mid-2027.

A phase 2 trial shows NNZ-2591 improves symptoms in children with Phelan-McDermid syndrome, paving the way for a phase 3 study.

Here's some of what is coming soon to NeurologyLive® this week.

Neurology News Network for the week ending January 10, 2025. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 9, 2026.

Bright Mind Biosciences reveals promising results for BMB-101 in treating drug-resistant seizures, paving the way for future clinical trials.

A recent analysis reveals fenfluramine's positive effects on executive functioning in adults with Lennox-Gastaut syndrome, independent of seizure reduction.

The director of the EEG/Epilepsy Unit in the Department of Clinical Neurosciences at Lausanne University Hospital in Switzerland discussed post-anoxic seizure management at 2025 AES Annual Meeting. [WATCH TIME: 3 minutes]